

Haemodynamic Effects of Dobutamine in Patients With Wild-type Transthyretin Amyloid Cardiomyopathy (ATTRwt)

NCT06318260

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Steen Hvitfeldt Poulsen
Enrollment	35 participants

Key Eligibility Criteria

Inclusion (6)

- ATTRwt, diagnosis confirmed by genetic testing, 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) scintigraphy and/or endomyocardial biopsy.
- Treated with loop diuretics.
- New York Heart Association class II-IV.
- Age \geq 65 years.
- Left ventricular ejection fraction (LVEF) $<$ 50 % and/or SVI assessed by echocardiography $<$ 35 ml/m².
- ... and 1 more (see full listing online)

Exclusion (5)

- Moderate to severe aortic stenosis (participants with aortic sclerosis will not be excluded).
- Other significant valvular diseases.
- Known severe coronary artery diseases: left main stem stenosis or 3-vessel disease, or recent acute myocardial infarction ($<$ 4 weeks).
- Contraindications to the use of dobutamine: Known allergy to dobutamine or sulfite, pheochromocytoma or ventricular tachycardia (VT).
- End stage renal disease (eGFR of less than 15 mL/min/1,73 m²).

Locations (1 total)

Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark